Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.
about
First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesSecond malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceNovel therapies in multiple myeloma for newly diagnosed nontransplant candidatesReiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma.Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyMaintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials.Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaThalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma.Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myelomaPhase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).Role of thalidomide in previously untreated patients with multiple myeloma.Front line treatment of elderly multiple myeloma in the era of novel agents.Treatment of newly diagnosed myeloma.Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.Role of autologous and allogeneic stem cell transplantation in myeloma.Initial therapy in multiple myeloma: investigating the new treatment paradigm.International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).Treatment of multiple myeloma: a comprehensive review.How best to use new therapies in multiple myeloma.Evolving therapeutic paradigms for multiple myeloma: back to the future.Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.The role of tandem stem cell transplantation for multiple myeloma patients.Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited.Stem cell transplantation for multiple myelomaLenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia.Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.Retracted publications in the drug literature.Impact of early relapse after auto-SCT for multiple myeloma.High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
P2860
Q24197999-996E9D54-2932-43DC-B9B6-EB7587BA4BA0Q24610430-DDD80327-4A6D-4CC5-B8F4-5E4D55BC091DQ33639796-4AF7D56E-5538-40C5-9FEC-AC5A6FBD4F35Q33990944-F7564354-EDFE-4848-99FF-9A381F394B0DQ34034447-5F24CAF7-61BD-4032-9552-3B05D5BD28FCQ34122646-16AA4CC1-A59D-4A6A-9AF6-0699C52BB2DCQ34973992-15EE7C6F-4BC8-43E7-AD16-A9F2C0DEC15AQ35097338-087DCAB0-1E12-4106-92C3-E9FB012BC9D6Q35932505-3CDAF7C6-166A-4C61-A579-BBB70E58F307Q36301287-4B89BD22-9EFF-47A0-995D-FC2B2893A218Q36765107-704DA7B1-15E7-4C9C-87EE-07C1C191DFA5Q37209935-A3B06837-3CE7-41B7-9A3D-FECD52069754Q37274353-D4867713-D761-41B3-865C-A1093EA62E10Q37280737-9AE6B6F1-EEF0-4C6E-A134-A45E52BFD248Q37300004-F39189DD-4929-413E-8C3C-01980266BB91Q37303213-EEB1EFB8-BC4A-42F9-ADA7-39A996FD7D00Q37324251-3D87EFD5-C9F3-41A8-810B-27F75C26F2C9Q37367737-675C9646-3C27-476B-A916-9EF328749DA1Q37370051-E39F575B-C309-499E-B3AA-5BAEC2C63515Q37375819-7F0BA964-33BA-4D54-B7AA-F05FD2E944DEQ37391117-248331FC-6469-4192-A644-4233D5B74444Q37411805-3690BEF6-69E4-4C7E-9068-13C26C664252Q37507513-72BE0B2D-96A5-4C97-903A-C11F6EB32334Q37530452-18EDE14B-9A39-416A-A965-0787DA2BB085Q37542173-BF320B2B-9BAA-4BAA-BCCD-FFAD1E945F54Q37723000-DCE6F029-3C81-4A09-89F2-05B3FCC7E12CQ38033590-1A3D7532-83B5-4423-9373-2EE834CD7557Q38148272-6D5C57E3-FF9D-4320-9BBE-92FF23328307Q38176293-E5B517B8-7B1A-4469-A13A-9B6DDCBB6396Q38677358-EB7B9DCE-C646-45BB-BA9C-1CA0E39920AFQ39576312-566FFAB3-DAC0-49A9-B167-AACD375A0144Q41819684-E3EFBF2F-6D73-42FB-B6E3-3118C95546F5Q42096911-5798E305-70E4-48E3-BE98-16E41A329DFCQ42580823-2B719097-7552-4CEC-94CA-EBA7A8309A48Q43078127-8B384E5C-FEDE-489C-BFED-C4747945414FQ47771466-3433858D-F385-4893-8C24-70BCEE263B28Q53469257-8A3889B5-8414-47A9-BBF5-4A7D733268FFQ53470095-A102BDBA-999B-4900-BCDE-C9531ED24465
P2860
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Single autologous stem-cell tr ...... ter randomized clinical trial.
@en
Single autologous stem-cell tr ...... ter randomized clinical trial.
@nl
type
label
Single autologous stem-cell tr ...... ter randomized clinical trial.
@en
Single autologous stem-cell tr ...... ter randomized clinical trial.
@nl
prefLabel
Single autologous stem-cell tr ...... ter randomized clinical trial.
@en
Single autologous stem-cell tr ...... ter randomized clinical trial.
@nl
P2093
P1433
P1476
Single autologous stem-cell tr ...... ter randomized clinical trial.
@en
P2093
Abdeladhim Ben Abdeladhim
Abderrahman Abdelkefi
Ahlem Amouri
Amel Lakhal
Assia Ben Hassen
Fahmi Msadek
Habib Ksouri
Halima El Omri
Hatem Belaaj
P304
P356
10.1182/BLOOD-2007-07-101212
P407
P577
2007-09-17T00:00:00Z